Abstract:Background: Recent studies have suggested that expression of the RAS protein activator like-1 gene (RASAL1) is decreased in gastric carcinoma tissues and cell lines, indicated a role in tumorigenesis and development of gastric cancer. Reduced expression of RASAL1 could result in aberrant increase of activity of RAS signaling pathways in cancer cells. However, the exact mechanism which induces down-regulation of the RASAL1 gene remains unclear. This study aimed to determine the methylation status and regulation of RASAL1 in gastric cancer. Materials and Methods: Using the methylation-specific polymerase chain reaction (MSP), the methylation status of CpG islands in the RASAL1 promoter in gastric cancers and paired adjacent non-cancerous tissues from 40 patients was assessed and its clinicopathological significance was analyzed. The methylation status of RASAL1 in gastric cancer lines MKN-28, SGC-790l, BGC-823, as well as in normal gastric epithelial cell line GES-1 was also determined after treatment with a DNA methyltransferase inhibitor, 5-aza-2'-doexycytidine (5-Aza-CdR). RAS activity (GAS-GTP) was assessed through a pull-down method, while protein levels of ERK1/2, a downstream molecule of RAS signaling pathways, were determined by Western blotting. Results: The frequencies of RASAL1 promoter methylation in gastric cancer and paired adjacent non-cancerous tissues were 70% (28/40) and 30% (12/40) respectively (P<0.05). There were significantly correlations between RASAL1 promoter methylation with tumor differentiation, tumor size, invasive depth and lymph node metastasis in patients with gastric cancer (all P<0.05), but no correlation was found for age or gender. Promoter hypermethylation of the RASAL1 gene was detected in MKN-28, SGC-790l and BGC-823 cancer cells, but not in the normal gastric epithelial cell line GES-1. Elevated expression of the RASAL1 protein, a decreased RAS-GTP and p-ERK1/2 protein were detected in three gastric cancer cell lines after treatment with 5-Aza-CdR. Conclusions: Aberrant hypermethylation of the RASAL1 gene promoter frequently occurs in gastric cancer tissues and cells. In addition, the demethylating agent 5-Aza-CdR can reverse the hypermethylation of RASAL1 gene and up-regulate the expression of RASAL1 significantly in gastric cancer cells in vivo. Our study suggests that RASAL1 promoter methylation may have a certain relationship with the reduced RASAL1 expression in gastric cancer.

Ras-induced Epigenetic Inactivation of the RRAD (Ras-related Associated with Diabetes) Gene Promotes Glucose Uptake in a Human Ovarian Cancer Model

Ras-related Associated with Diabetes Gene Acts As a Suppressor and Inhibits Warburg Effect in Hepatocellular Carcinoma.

Abstract 2389: LINC00901 Regulates Glucose Metabolism in Pancreatic Cancer

Linc00901 Regulates Glucose Metabolism In Pancreatic Cancer.

RRAD suppresses the Warburg effect by downregulating ACTG1 in hepatocellular carcinoma.

Epigenetic Silencing of a Ca2+-regulated Ras GTPase-activating Protein RASAL Defines a New Mechanism of Ras Activation in Human Cancers

Oncogenic Ras Suppresses ING4-TDG-Fas Axis to Promote Apoptosis Resistance.

RRAD inhibits aerobic glycolysis, invasion, and migration and is associated with poor prognosis in hepatocellular carcinoma

RRAD inhibits the Warburg effect through negative regulation of the NF-kappa B signaling

The enhanced energy metabolism in the tumor margin mediated by RRAD promotes the progression of oral squamous cell carcinoma

O-GlcNAcylation Promotes Pancreatic Tumor Growth by Regulating Malate Dehydrogenase 1

REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells.

Tumor Suppressor P53 Negatively Regulates Glycolysis Stimulated by Hypoxia Through Its Target RRAD

Hypermethylation and clinicopathological significance of RASAL1 gene in gastric cancer.

Abstract B76: High Glucose Induces Breast Cancer Progression Through Upregulating PP2Cδ

High Glucose-Upregulated PD-L1 Expression Through RAS Signaling-Driven Downregulation of PTRH1 Leads to Suppression of T Cell Cytotoxic Function in Tumor Environment

YTHDC1-mediated augmentation of miR-30d in repressing pancreatic tumorigenesis via attenuation of RUNX1-induced transcriptional activation of Warburg effect

RGS11 Imparts Anti-Tumorigenic Features in Pancreatic Cancer

N6-methyladenosine-modified ALDH9A1 modulates lipid accumulation and tumor progression in clear cell renal cell carcinoma through the NPM1/IQGAP2/AKT signaling pathway

Retinoic acid‐related orphan receptor alpha reprograms glucose metabolism in glutamine‐deficient hepatoma cells

RNAa and Vector-Mediated Overexpression of DIRAS1 Suppresses Tumor Growth and Migration in Renal Cell Carcinoma